U-95666E: A potential anti-parkinsonian drug with anxiolytic activity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 21, Issue 5, 1997, Pages 873-883

  Sethy, Vimala H ^a   Ellerbrock, Brenda R ^a   Wu, Haiyan ^a  

^a PFIZER INC   (United States)

Author keywords

Cerebellar cGMP; Dopamine agonists; Parkinson's disease; Striatal acetylcholine

Indexed keywords

ACETYLCHOLINE; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; APOMORPHINE; BROMOCRIPTINE; CYCLIC GMP; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PERGOLIDE; PRAMIPEXOLE; RACLOPRIDE; RESERPINE; U 95666E; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG ANTAGONISM; DRUG SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; RAT; RECEPTOR INTRINSIC ACTIVITY; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA; TRANQUILIZING ACTIVITY;

ACETYLCHOLINE; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPARKINSON AGENTS; BENZIMIDAZOLES; CEREBELLUM; CYCLIC GMP; DENERVATION; DOPAMINE AGONISTS; ELECTROSHOCK; MALE; MICE; NEOSTRIATUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; STRESS; SYMPATHECTOMY, CHEMICAL;

EID: 0030748465     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(97)00086-9     Document Type: Article

References (25)

1. AGID, Y., CERVERA, P., HIRSCH, E., JAVOY-AGID, F., LEHERICY, S., RAISMAN, R. and RUBERG, M. (1989) Biochemistry of Parkinson's disease 28 years later: a critical review. Mov. Disord. 4: 126-144.
2. BURKARD, W. P., BONETTI, E. P. and HAEFELY, W. (1985) The benzodiazepine antagonist RO 15 1788 reverses the effect of methy-β-carboline-3-carboxylate but not of harmaline on cerebellar cGMP and motor performance in mice. Eur. J. Pharmacal. 109:241-247.
3. 2 receptor subtype: Increase in post-synaptic response in parkinson's disease (PD) model. Neurosecience 21: 853.
4. DAWSON, V. L., DAWSON, T. M., FILLOUX, F. M. and WAMSLEY, J. K. (1988) Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sci. 42: 1933-1939.
5. DEPOORTERE, R., PERRAULT, G. and SANGER, D. J. (1996) Behavioral effects in the rats of the putative Dopamine D-3 receptor agonist 7-OH-DPAT comparison with quinpirole and apomorphine. Psychopharmacol. 124: 231-240.
6. EVA, C., HADJICONSTANTINOU, M., NEFF. N. H. and MEEK, J. L. (1984) Acetylcholine measurement by high pressure liquid chromatography using an enzyme-loaded post-column reactor. Anal. Biochem. 143: 320-324.
7. 1 dopamine receptor activity of anti-parkinson drugs. Soc. Neurosci. Abst. 21: 1254.
8. HORNYKIEWICZ, O. and KISH, S. J. (1986) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45: 19-34.
9. JENNER, P. (1995) The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45: S6-S12.
10. MacLENNAN, A. J., LEE, N., VINCENT, S. R. and WALKER, D. W. (1994) D2 dopamine receptor mRNA distribution in cholinergic and somatostatinergic cells of rat caudate-putamen and nucleus accumbens. Neurosci. Lett. 180: 214-218.
11. MARSDEN, C. D. and PARKES, J. D. (1977) Success and problems of long-term therapy in Parkinson's disease. Lancet 2: 345-49.
12. MENZA, M. A., ROBERTSON-HOFFMAN, D. E. and BONAPACE, A. E. (1993) Parkinson's disease and anxiety: comorbidity with depression. Biol. Psychiat. 34: 465-470.
13. PETERSON, E. N., JENSEN, L. H., HONORE, T., BRAESTRUP, C., KEHR, W., STEPHENS, D. N., WACHTEL, H., SEIDELMAN, D. and SCHMIECHEN, R. (1984) ZK 91296, a partial agonist at benzodiazepine receptor. Psychopharmacol. 83: 240-248.
14. ROSENGARTEN, H., SCHWEITZER, J. W. and FRIEDHOFF, A. J. (1983) Induction of oral dyskinesias in naive rats by D1 receptor stimulation. Life Sci. 39: 29-35.
15. SCATTON, B. (1982) Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. J. Pharmacal. Exp. Ther. 220: 197-202.
16. SCATTON, B., CLAUSTRE, Y., DENNIS, T. and NISHIKAWA, T. (1986) Zolpidem, a novel nonbenzodiazepine hypnotic, II. Effect on cerebellar cGMP levels and cerebral monoamines. J. Pharmacol. Exp. Ther. 237: 659-665.
17. SETHY, V. H. and FRANCIS, J. W. (1988) Regulation of brain acetylcholine concentration by muscarinic receptors. J. Pharmacol. Exp. Ther. 246:243-248.
18. SETHY, V. H., FRANCIS, J. W. and ELFRING, G. (1987) Onset and duration of action of benzodiazepines as determined by inhibition of [3H]-flunitrazepam binding. Drug Dev. Res. 10: 117-121.
19. SETHY, V. H. and OIEN, T. T. (1991) Role of cGMP in the mechanism of anxiolytic activity of U-78875. Pharmacol. Biochem. Behav. 39: 379-382.
20. SETHY, V. H. and Van WOERT, M. (1974) Regulation of striatal acetylcholine concentration by dopamine receptor. Nature 251: 529-530.
21. SIEMERS, E. R., SHEKHAR, A., QUAID, K. and DICKSON, H. (1993) Anxiety and motor performance in Parkinson's disease. Mov. Disord. 8: 501-506.
22. STEIN, M. S., HEUSER, I. J., JUNCOS, J. L. and Uhde T. W. (1990) Anxiety disorders in patient with Parkinson's disease. Am. J. Psychiat. 147: 217-220.
23. WOLTERS, E. C., TISSINGH, G., BERGMANS, P. L. M. and KUIPER, M. A. (1995) Dopamine agonists in Parkinson's disease. Neurology 45: 528-534.
24. 2 dopamine agonist, increases acetylcholine concentration in rat corpus striatum. J. Pharm. Pharmacol. 35: 328-329.
25. 2 dopamine receptor mRNA. Neurochem. Int. 22: 301-311.